Furthermore, NT-proBNP has been established as a significant predictor of cardiovascular events and heart failure in patients with AS, emphasizing the importance of comprehensive risk assessment and management strategies that incorporate these metabolic and clinical biomarkers to optimize patient outcomes [30]. This evidence concerns the gene NPPB and aortic stenosis.